AMSTERDAM, January 22 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that Dr. Ronald H.W. Lorijn will for personal reasons retire as chief executive officer, effective February 1, 2009. Prof. Sander van Deventer, AMT's chief scientific officer and co-founder of the company, has been named chief executive officer on an interim basis.
Since Ronald Lorijn started in 2005, AMT changed from a small, one-product company into a leading gene therapy company with a richly filled R&D pipeline and lead product Glybera(R). The Company reached within four years a number of key milestones: successful financing round in 2006; successful IPO in 2007; multiple R&D strategic international collaborations; and Glybera(R) close to filing for marketing approval in Europe, USA and Canada.
"Under Ronald's leadership the company has delivered outstanding results for which we are very grateful. We look forward to continuing the execution of the company strategy by building on this strong foundation," said Ferdinand Verdonck, chairman of the Supervisory Board.
"I regret that personal reasons prevent me from being actively involved in the next level of growth of AMT. I wish this great company and its people a lot of success in achieving the goal we have set ourselves: offering cures for patients suffering from serious, debilitating diseases by making gene therapy available to them", said Ronald Lorijn.
Sander van Deventer: "I look forward to guiding AMT at this important stage with the clinical trial for Glybera(R) and the filing of the marketing authorization dossier for this product. I am focused on successfully developing our drug candidates into cures for serious diseases together with the team of excellent and experienced people at our company."
Ferdinand Verdonck adds: "Sander van Deventer
|SOURCE Amsterdam Molecular Therapeutics B.V|
Copyright©2009 PR Newswire.
All rights reserved